NASDAQ$CLDX
Celldex Therapeutics Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.
Celldex Therapeutics reported fourth-quarter financial results, with total revenue of $0.3 million and a net loss of $20.1 million, or ($0.43) per share. The company's cash, cash equivalents, and marketable securities totaled $408.3 million as of December 31, 2021, and they anticipate sufficient funds to support operations through 2025.
- CDX-0159 Phase 1b study demonstrated a 95% complete response rate in chronic inducible urticaria.
- Raised $287 million in gross proceeds from a public offering in July 2021.
- On track to initiate Phase 2 urticaria programs in the second quarter of 2022.
- Cash, cash equivalents and marketable securities as of December 31, 2021 were $408.3 million.
Headline financials
Revenue & EPS history
Celldex · Revenue · Quarterly
$333K
Forward guidance
Celldex believes that the cash, cash equivalents and marketable securities at December 31, 2021 are sufficient to meet estimated working capital requirements and fund planned operations through 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+1.3%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+1.7%
Avg return
30 days after
59%
38 / 64 earnings
Positive
+35.2%
Q4 2023
Best reaction
-21.5%
Q3 2014
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.2% | -7.0% | -16.8% | |
| Q4 2025 | -0.6% | -6.1% | -1.7% | |
| Q3 2025 | +7.6% | +12.7% | +23.2% | |
| Q1 2025 | +2.2% | -0.4% | -0.5% | |
| Q4 2024 | -1.6% | -3.1% | -3.4% | |
| Q3 2024 | +4.1% | +3.1% | +5.3% | |
| Q2 2024 | +2.7% | +3.8% | +36.5% | |
| Q1 2024 | -0.8% | -6.2% | -22.4% | |
| Q4 2023 | +35.2% | +37.4% | +10.7% | |
| Q3 2023 | +10.2% | +23.1% | +35.9% | |
| Q2 2023 | -6.5% | -7.4% | -13.3% | |
| Q1 2023 | +5.8% | +5.3% | +5.5% | |
| Q4 2022 | +7.9% | +8.7% | -17.4% | |
| Q3 2022 | +9.4% | +5.6% | +7.5% | |
| Q2 2022 | -3.8% | +1.7% | -17.7% | |
| Q1 2022 | -10.3% | -10.6% | -23.4% | |
| Q4 2021 | +4.7% | +0.5% | +14.7% | |
| Q3 2021 | +0.6% | -7.6% | -18.1% | |
| Q2 2021 | +6.2% | +3.7% | +20.9% | |
| Q1 2021 | -1.3% | -3.3% | +0.8% | |
| Q4 2020 | -16.9% | -4.0% | +30.4% | |
| Q3 2020 | +1.4% | +9.6% | +10.3% | |
| Q2 2020 | -3.5% | -12.3% | -7.5% | |
| Q1 2020 | +0.4% | +0.4% | +29.4% | |
| Q4 2019 | +3.4% | -7.3% | +68.2% | |
| Q3 2019 | -2.5% | -5.0% | -7.9% | |
| Q2 2019 | +6.2% | +1.4% | +2.9% | |
| Q1 2019 | -6.6% | -15.4% | -36.1% | |
| Q4 2018 | +9.0% | +4.3% | -7.3% | |
| Q3 2018 | +15.2% | +3.0% | -21.2% | |
| Q2 2018 | +0.0% | -6.7% | +2.2% | |
| Q1 2018 | -5.2% | -7.8% | -15.6% | |
| Q4 2017 | +14.1% | +17.0% | -17.4% | |
| Q3 2017 | +15.5% | +14.7% | +23.1% | |
| Q2 2017 | +2.4% | -0.8% | +11.7% | |
| Q1 2017 | +0.7% | +2.9% | -23.5% | |
| Q4 2016 | +1.8% | +2.1% | -2.1% | |
| Q3 2016 | +22.3% | +39.8% | +21.7% | |
| Q2 2016 | +0.4% | -4.3% | -21.5% | |
| Q1 2016 | -8.9% | — | — | |
| Q4 2015 | +10.9% | — | — | |
| Q3 2015 | +5.4% | — | — | |
| Q2 2015 | -21.4% | — | — | |
| Q1 2015 | +0.3% | — | — | |
| Q4 2014 | +0.9% | — | — | |
| Q3 2014 | -21.5% | — | — | |
| Q2 2014 | +4.0% | — | — | |
| Q1 2014 | -3.3% | — | — | |
| Q4 2013 | -5.2% | — | — | |
| Q3 2013 | +4.2% | — | — | |
| Q2 2013 | -6.7% | — | — | |
| Q1 2013 | +2.5% | — | — | |
| Q4 2012 | +13.3% | — | — | |
| Q3 2012 | +5.9% | — | — | |
| Q2 2012 | -2.6% | — | — | |
| Q1 2012 | +1.5% | — | — | |
| Q4 2011 | +2.6% | — | — | |
| Q3 2011 | -3.6% | — | — | |
| Q2 2011 | -15.9% | — | — | |
| Q1 2011 | +0.5% | — | — | |
| Q4 2010 | -5.4% | — | — | |
| Q3 2010 | +7.6% | — | — | |
| Q2 2010 | -3.9% | — | — | |
| Q1 2010 | -2.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro